Complete coverage on

Avandia

Latest Stories

Fortune: Why the EU banned Avandia but the FDA didn'tupdated: Fri Sep 24 2010 13:40:00

Avandia has taken some beatings over the years, but it pretty much took a fatal blow yesterday. That's when the Food and Drug Administration ruled to keep the drug on the market in the United States with some serious restrictions.

Concerned about Avandia? Here are other optionsupdated: Fri Sep 24 2010 13:03:00

Edward Darden started taking the diabetes drug Avandia in 2006 to help control his blood sugar and was doing just fine, he said. But he became concerned when he saw warnings linking the drug to a 43 percent increased risk of heart attack, following the 2007 release of a study in the New England Journal of Medicine.

FDA restricts diabetes drugupdated: Fri Sep 24 2010 13:03:00

CNN's Dr. Sanjay Gupta explains the controversy behind the diabetes drug Avandia.

Fortune: Avandia: a PR mess for Glaxo, but not a financial oneupdated: Wed Sep 15 2010 13:44:00

GlaxoSmithKline is on the hook for Avandia, a drug that helps diabetes patients regulate blood sugar levels, but also causes heart problems. Critical reviews in major medical journals have repeatedly challenged its safety, and mainstream media have picked up on the studies in scathing articles. GSK has tried to defend the drug from the attacks, but there's only so much the company can do.

FDA panel split on Avandiaupdated: Thu Jul 15 2010 07:55:00

FDA officials will decide the ultimate fate of the diabetes drug Avandia. CNN's Dr. Sanjay Gupta reports.

Split decision from FDA panel on Avandiaupdated: Thu Jul 15 2010 07:55:00

A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending different changes in how it's prescribed.

CNNMoney: FDA panel split on Avandia decisionupdated: Wed Jul 14 2010 17:14:00

A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending changes in how it's prescribed.

Fortune: What the Avandia ruling means for Big Pharmaupdated: Wed Jul 14 2010 16:09:00

In a widely-anticipated ruling, a panel of experts will decide Wednesday whether or not to recommend that the FDA pull GlaxoSmithKline's blockbuster diabetes drug Avandia off the market in the United States.

FDA researcher blasts manufacturer's tests on diabetes drugupdated: Tue Jul 13 2010 19:46:00

A prominent Food and Drug Administration researcher sharply criticized a safety study by the manufacturer of the diabetes drug Avandia on Tuesday as an FDA panel weighed whether to yank the drug from the market.

Key diabetes drug study was flawed, review chargesupdated: Fri Jul 09 2010 18:42:00

The popular diabetes drug Avandia may be far more dangerous to patients than reported in a study touted by the drug's manufacturer, according to a strongly worded report posted Friday by the Food and Drug Administration.

Avandia and diabetes: Was revolution worth the risks?updated: Fri Jul 09 2010 08:50:00

A decade after critics first accused the Food and Drug Administration of downplaying side effects from Avandia, the agency says it will reveal on Friday the data it is reviewing ahead of an advisory panel meeting about the safety of the popular diabetes drug.

CNNMoney: Senators challenge safety of GlaxoSmithKline's Avandiaupdated: Mon Feb 22 2010 16:42:00

The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, a Senate committee report released Saturday says.

Senate report links diabetes drug Avandia to heart attacksupdated: Sat Feb 20 2010 16:39:00

The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, according to a Senate committee report released Saturday.

GlaxoSmithKline earnings dropupdated: Thu Feb 07 2008 21:38:00

CNN's Charles Hodson talks with GlaxoSmithKline CEO Jean-Pierre Garnier about his company's recent drop in earnings.

Diabetes drug market: Lizard spit and bongsupdated: Wed Oct 31 2007 09:54:00

America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."

Generic drug controversyupdated: Wed Oct 24 2007 09:16:00

A study finds great differences between one generic drug and its brand-name counterpart. CNN's Dr. Sanjay Gupta reports.

CNNMoney: Study: Mixed results on diabetes drug safetyupdated: Wed Sep 12 2007 00:58:00

Actos and Avandia have entered the spotlight again, as studies published in a leading medical journal pit the two diabetes drugs against each other by comparing their cardiovascular risks.

CNNMoney: FDA to strengthen diabetes drug warningsupdated: Tue Aug 14 2007 04:40:00

The FDA said on Tuesday that GlaxoSmithKline and Takeda agreed to strengthen heart failure warnings on their diabetes drugs, Avandia and Actos.

CNNMoney: Glaxo stock surges on Avandia voteupdated: Tue Jul 31 2007 00:22:00

GlaxoSmithKline's stock rose nearly 4 percent on Tuesday, the day after FDA advisors voted to keep its diabetes drug Avandia on the market.

CNNMoney: Keep Avandia on market, say FDA advisersupdated: Mon Jul 30 2007 07:38:00

Food and Drug Administration panelists voted Monday that GlaxoSmithKline's diabetes drug Avandia should remain on the market, despite an analysis showing links to increased risk of heart attack.

CNNMoney: FDA reviewer pans Avandiaupdated: Sun Jul 29 2007 21:20:00

GlaxoSmithKline Plc's widely used diabetes drug Avandia should be pulled off the market, Food and Drug Administration reviewer David Graham said in a presentation prepared for delivery Monday.

CNNMoney: Glaxo prepares for face-to-face with FDAupdated: Fri Jul 20 2007 01:57:00

GlaxoSmithKline is getting ready for a face-to-face with the FDA about its diabetes drug Avandia, which has been on the hot seat since a study blamed the drug for increasing the risk of heart attack.

CNNMoney: Heart doctors spar over diabetes drugupdated: Mon Jun 25 2007 07:43:00

Debate over the heart attack risk associated with the GlaxoSmithKline diabetes drug Avandia took center stage Monday at the annual meeting of the American Diabetes Association.

CNNMoney: Merck sees long-term benefits from Januviaupdated: Sat Jun 23 2007 02:58:00

Merck's new drug Januvia controls blood-sugar in two-thirds of diabetics when combined with the drug metformin, the company said Saturday.

Time.com: Medical Expert to Testify Against Glaxoupdated: Wed Jun 06 2007 18:05:00

The controversy surrounding GlaxoSmithKline's diabetes drug Avandia mounted Wednesday as a medical expert prepared to tell lawmakers the British drug maker threatened him with legal action when he first raised questions about the treatment's safety

Time.com: FDA Declines Cancer Vaccine Reviewupdated: Thu May 31 2007 18:10:00

GlaxoSmithKline PLC revealed Thursday that the U.S. Food and Drug Administration has declined to grant a priority review to its experimental cancer vaccine Cervarix

Time.com: Is Avandia the Next Vioxx?updated: Fri May 25 2007 15:40:00

With concerns raised about heart risks of a popular diabetes drug, GlaxoSmithKline and the FDA scramble to respond

CNNMoney: Merck, Lilly could benefit from Avandia flapupdated: Tue May 22 2007 12:39:00

The recently published study results that link GlaxoSmithKline's blockbuster diabetes drug Avandia to heart attacks could shift market share to rivals Merck, Lilly and Amylin, despite questions surrounding the data, analysts say.

CNNMoney: Diabetes split could shake up marketupdated: Fri Jun 24 2005 15:13:00

Two blockbuster diabetes drugs, Actos and Avandia, have locked horns for years in a very lucrative market but an impending shift in corporate partnerships and the introduction of new blockbusters could tilt the balance, industry analysts said.

We recommend